Network meta-analysis of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation

被引：0
|
作者：
Marx, S.
Diener, H. -C. [2 ]
Harenberg, J.
Lip, G. [3 ]
Marder, V. [4 ]
Wehling, M.
Weiss, C. [1 ]
机构：
[1] Univ Heidelberg, Med Fac Mannheim, Dept Biometr & Stat, D-6800 Mannheim, Germany
[2] Univ Clin Essen, Dept Neurol, Essen, Germany
[3] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：815 / 815
页数：1
相关论文
共 50 条
  • [31] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [32] ADHERENCE TO RIVAROXABAN, DABIGATRAN, AND APIXABAN FOR STROKE PREVENTION IN INCIDENT, TREATMENT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION
    Brown, J.
    Shewale, A. R.
    Talbert, J.
    VALUE IN HEALTH, 2016, 19 (07) : A638 - A638
  • [33] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [34] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [35] Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation
    Meng, Shih-Wei
    Lin, Ting-Tse
    Liao, Min-Tsun
    Chen, Ho-Min
    Lai, Chao-Lun
    ACTA CARDIOLOGICA SINICA, 2019, 35 (01) : 42 - 54
  • [36] The Efficacy and Safety of Oral Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Scheduled for Electrical Cardioversion
    Enomoto, Yoshinari
    Ito, Naoshi
    Fujino, Tadashi
    Noro, Mahito
    Ikeda, Takanori
    Sugi, Kaoru
    INTERNAL MEDICINE, 2016, 55 (15) : 1953 - 1958
  • [37] Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
    Villines, Todd C.
    Ahmad, Azhar
    Petrini, Michaela
    Tang, Wenbo
    Evans, Amber
    Rush, Toni
    Thompson, David
    Oh, Kelly
    Schwartzman, Eric
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (02) : 80 - 90
  • [38] Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation
    Deitelzweig, S.
    Kang, A.
    Jiang, J.
    Gao, C.
    Luo, X.
    Atreja, N.
    Han, S.
    Cheng, D.
    Lip, G.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [39] Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
    Deitelzweig, Steven
    Kang, Amiee
    Jiang, Jenny
    Gao, Chuan
    Luo, Xuemei
    Atreja, Nipun
    Han, Stella
    Cheng, Dong
    Loganathan, Saarusri R.
    Lip, Gregory Y. H.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)
  • [40] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
12345